The brief

Analyst view

• One of the world's largest biotech, $38.2B+ 2026 revenue guidance. Spans inflammation, cardiology, obesity, oncology.
• MariTide, a monthly GLP-1/GIP agonist, in Phase 3 for obesity, T2D, heart failure, kidney disease. Readout early 2027.
• Public since 1983 (AMGN), listed NASDAQ. CEO Robert Bradway since 2012.

Technical approach

As reported

Dual mechanism

GLP-1 agonist + GIP antagonist

Activates GLP-1 receptors to slow stomach and signal fullness. Blocks GIP to suppress a second hunger pathway.

Long-acting format

Antibody-peptide conjugate

Two peptides fused to IgG2 antibody. Fc region binds neonatal receptor for recycling, extending half-life. Monthly dosing.

Scope

Multi-indication trials

Phase 3 explores obesity, T2D, heart failure, kidney disease, sleep apnea. One drug for many metabolic conditions.